agilon health, inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Aug-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
agilon's ownership story is one of dramatic wealth destruction and a subsequent leadership-driven rescue effort. Founded in 2016 with backing from private equity firm Clayton Dubilier & Rice, which took it public in 2021, agilon saw its market value collapse from nearly 9 billion dollars at the IPO to under 500 million dollars, a roughly 95 percent decline, as its business model buckled under rising medical costs.That collapse triggered the defining ownership event: in 2025, chief executive Steven Sell stepped down, and co-founder and board chairman Ronald A. Williams, a widely respected former chief executive of the insurer Aetna, took over as executive chairman to lead a recovery while the board searched for permanent leadership. Williams's deep managed-care experience is precisely what a company grappling with mispriced medical risk needs, and his stepping into an operating role signals the seriousness of the situation.For investors, the ownership picture is of a distressed company under experienced crisis leadership, with a dispersed base that has been badly burned and a former sponsor still holding a stake. The reset underway, exiting unprofitable arrangements, tightening contracts, and rebuilding toward profitability, is being driven from the top by Williams. Owning agilon now is a high-risk bet that seasoned leadership can fix a broken model and restore value from a deeply depressed base, or a wager that the value-based-care thesis, though painful to execute, is ultimately sound.
Direct Owners
Institutional Shareholders
Shareholder Analysis
agilon shareholders own a cautionary tale about the difficulty of bearing medical risk, and the 2025 results lay the damage bare. Revenue was 5.93 billion dollars, down 2 percent, but the profitability collapsed: the company posted a gross loss of 160 million dollars, a medical margin of negative 57 million dollars, a net loss of 391 million dollars, and an adjusted EBITDA loss of 296 million dollars that nearly doubled from the prior year. Membership shrank 5 percent to 625,000 as agilon deliberately exited unprofitable markets.Understanding what went wrong requires understanding the model. agilon partners with independent primary-care physician groups and moves them into full-risk Medicare Advantage arrangements, receiving the fixed premium for seniors' care and taking responsibility for their total cost of care, profiting only if it keeps them healthy and their costs below that premium. This model works when medical costs are predictable, but from 2023 to 2025 senior medical utilization surged, inpatient stays and large claims drove a medical cost trend of 6.5 percent, and agilon's costs blew through the fixed revenue it received, producing large losses on the insurance risk it had assumed.The question for shareholders is whether the model is broken or merely mispriced, and the 2026 outlook offers cautious hope. Management is executing a hard reset, exiting structurally unprofitable contracts, tightening payer terms to secure premiums at or above benchmark rates, cutting costs, and shrinking membership to a profitable core, and it guides medical margin to turn solidly positive and adjusted EBITDA toward breakeven or better in 2026. The bull case is that value-based care is a sound long-term model that agilon can make profitable with disciplined pricing, and that the distressed valuation offers large upside if the reset works. The bear case is that bearing insurance risk on seniors' health is inherently treacherous, that agilon has repeatedly underestimated costs, and that the model may never sustainably work. Shareholders are underwriting a genuine recovery with real execution risk from a near-death starting point.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
agilon does not compete on brand in a consumer sense but on the strength of its model and its partnerships with physicians, and understanding that model is essential to understanding the company. Its core offering is the Total Care Model, through which agilon partners with existing, trusted community primary-care physician groups and provides them the capital, technology, data, and infrastructure to succeed under full-risk Medicare Advantage contracts, taking on the financial risk for their senior patients' total care.The strategic appeal of this approach is that agilon empowers established local physicians, who already have their patients' trust, rather than building or buying clinics itself, a capital-lighter, partnership-based model distinct from competitors like the clinic-owning Oak Street Health. agilon's platform provides the analytics and support that let community doctors thrive in value-based care, and its long-term partnership agreements are meant to create durable, aligned relationships.The difficulty the recent crisis exposed is that agilon's success depends entirely on accurately predicting and managing medical costs across its risk pool, and when those costs surged, the model's promise turned into large losses. The strategic reset involves being far more disciplined about which markets, payers, and contracts agilon takes on, prioritizing profitable, well-priced risk over growth. agilon's proposition, enabling community physicians to succeed in value-based care while it manages the risk, remains conceptually powerful, but the company is learning, expensively, that executing it profitably requires far tighter control of the medical-cost risk at its core.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
agilon competes in the crowded and troubled field of value-based care for seniors, where a range of companies, from clinic owners to physician enablers to Medicare Advantage insurers, are chasing the same goal of profiting by keeping seniors healthy at lower cost, and where many have stumbled on the same rocks agilon hit. Its competitors include physician-enablement companies like Privia Health and Astrana Health, Medicare Advantage-focused insurers like Alignment Healthcare, and clinic operators like the CVS-owned Oak Street Health.agilon's distinctive competitive positioning is its partnership model: rather than owning clinics or employing physicians, it partners with established independent primary-care groups, a capital-lighter approach that leverages existing physician-patient trust. In principle, this gives agilon a scalable way to expand and aligns it with community doctors, differentiating it from more capital-intensive, clinic-owning rivals.But the competitive reality is that the entire sub-sector has struggled with the fundamental challenge agilon faces, accurately pricing and managing medical risk in an environment of rising costs and tightening Medicare Advantage economics, and several competitors have faced similar losses or been absorbed by larger healthcare companies. agilon's competitive future depends less on beating specific rivals than on solving the industry-wide problem of making value-based senior care sustainably profitable. Its competitive answer is a more disciplined, profitability-focused version of its partnership model, and its survival and success hinge on proving that the model, executed with proper risk discipline, can work where it and many peers previously faltered.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
agilon's growth story has been about organic expansion through physician partnerships rather than acquisitions, which distinguishes it from clinic-acquiring rivals and shapes both its model and its recent troubles. Rather than buying medical groups or clinics, agilon grows by signing long-term partnership agreements with existing independent primary-care physician groups and entering new geographic markets, providing them the platform to take on value-based care.This partnership-based, capital-light growth model was central to agilon's rapid expansion in its early years, as it added physician partners and markets quickly, scaling revenue toward 6 billion dollars. But that same rapid, growth-focused expansion contributed to its problems, as agilon took on risk in markets and contracts that proved unprofitable when medical costs rose, and the current reset explicitly involves reversing some of that expansion by exiting unprofitable markets.The strategic lesson agilon is absorbing is that its model requires disciplined, profitable growth rather than growth for its own sake, and its recent moves are about pruning, exiting markets and contracts, rather than acquiring. For investors, the key point is that agilon's value creation, and destruction, has come from the terms and management of its physician partnerships and risk contracts, not from M&A, so the recovery hinges on operational discipline in contracting and cost management rather than on dealmaking. The absence of acquisitions keeps the story focused squarely on whether agilon can make its core partnership-and-risk model profitable.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
agilon's corporate history is short and, in structural terms, straightforward, reflecting a company built organically and reshaped by crisis rather than by mergers. It was founded in 2016 with backing from private equity firm Clayton Dubilier & Rice, assembled from earlier value-based-care assets into a platform for partnering with primary-care physicians, and it went public in 2021 amid enthusiasm for value-based care.The company grew rapidly through organic expansion, adding physician partners and markets rather than pursuing acquisitions, so its structure remained that of a focused value-based-care enabler. The defining structural developments have not been transactions but the crisis-driven reset of 2025, the leadership change that brought co-founder Ronald Williams into an executive role, and the strategic decision to exit unprofitable markets and contracts, effectively shrinking the company to a more sustainable core.For investors, the structural story is that agilon is not a complex, acquisition-built enterprise but a focused company whose structure is being rationalized in response to its financial troubles. The absence of mergers or spin-offs means the recovery is an operational one, reshaping the portfolio of markets and contracts rather than the corporate structure. agilon's future structural questions may include whether it remains independent or, like some struggling peers, becomes an acquisition target for a larger healthcare organization seeking value-based-care capabilities, but for now its structure reflects a company focused on fixing its core business.
Ownership History
Ownership History Analysis
agilon health was founded in 2016, backed by private equity firm Clayton Dubilier & Rice, on a compelling premise: that partnering with trusted community primary-care physicians and empowering them to take on full risk for their senior patients' care could improve outcomes and lower costs, capturing value in the large and growing Medicare Advantage market. The idea resonated, and agilon expanded rapidly, going public in 2021 to considerable enthusiasm.The growth, however, outran the company's ability to manage the medical risk it was assuming. As senior medical costs surged from 2023 onward, agilon's expenses overwhelmed its fixed revenues, producing mounting losses that shattered investor confidence and sent the stock down roughly 95 percent from its IPO, a catastrophic collapse that forced a reckoning.Today agilon is a chastened company in the midst of a painful reset, led by veteran executive Ronald Williams, exiting unprofitable markets, tightening its contracts, and trying to prove that value-based care can be made sustainably profitable, with 2026 guidance pointing toward improvement. Its history is a vivid illustration of both the promise and the peril of value-based care, a model that aligns incentives and could transform senior healthcare, but that punishes any company that misjudges the difficult, unforgiving economics of bearing medical risk. agilon's next chapter will determine whether it becomes a recovery success or a casualty of that challenge.
Ownership Explained
agilon health is a widely held company listed on the New York Stock Exchange with no controlling shareholder, though its former private equity sponsor, Clayton Dubilier & Rice, remains a significant owner. Its stock has collapsed since its 2021 IPO. Co-founder and chairman Ronald A. Williams, a former Aetna chief executive, serves as executive chairman following a 2025 leadership change. Founded in 2016, agilon partners with primary care physicians to deliver value-based care to seniors.
agilon's owners have endured a brutal collapse, with the stock down roughly 95 percent from its IPO as the company's medical costs overwhelmed its revenue. That crisis forced a leadership change, with veteran healthcare executive Ronald Williams stepping in as executive chairman, and a strategic reset toward profitability. For shareholders, ownership now means backing a distressed but potentially salvageable value-based-care business as new leadership exits unprofitable markets, tightens contracting, and tries to prove the model can work sustainably.